UNSPSC 51102860: Loteprednol/tobramycin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP350. This VA Drug Class (OP350) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL OPHTHALMIC.

UNSPSC 51102860 Loteprednol/tobramycin, a Commodity code, designates a specific ophthalmic antibiotic-corticosteroid combination, yet recent state and local activity under this code shows minimal alignment with the pharmaceutical classification itself. The four recent opportunities tagged to this code span naloxone kits and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), medical and first aid supplies including respiratory and cardiac equipment (City of Tampa Fire Department), and multi-source generic pharmaceuticals and OTC products through a cooperative purchasing alliance (Minnesota Multistate Cooperative Purchasing Alliance). State and local buyers using this code range from county health departments and city fire rescue divisions to state HHS agencies and cooperative purchasing organizations serving multiple jurisdictions. The actual procurement activity reflects broad medical supply and pharmaceutical distribution rather than ophthalmologic products, suggesting either classification drift in how jurisdictions tag opportunities or a code mismatch in the source data itself.

The geographic spread of recent activity spans Florida, Texas, Minnesota, and Oregon, with the most developed opportunity being Minnesota's cooperative purchasing vehicle. Representative recent solicitations include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for naloxone and drug deactivation systems with quarterly deliveries; the City of Tampa's Bid 26-P-00145 (posted March 25, 2026, due March 13, 2026) for medical and first aid supplies to the Fire Department Rescue Division with an estimated contract value of $700,000.00 and SLBE set-aside designation; Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) for direct-to-manufacturer prescription capabilities; and Minnesota MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic pharmaceuticals and OTC products through authorized wholesalers with evaluations weighted heavily on price competitiveness (75 percent) and a two-year contract term. The code shows recent activity but limited thematic coherence with loteprednol/tobramycin specifically.